热门资讯> 正文
DexCom首席执行官请病假
2025-09-16 18:50
- 德康医疗(DXCM) 0
- 塞拉尼斯(CE) 0
- 纳比特(NA) 0
- DexCom (NASDAQ:DXCM) announced on Tuesday that Jacob Leach, its President and Chief Operating Officer, will lead the company on an interim basis as its CEO and Chairman of the Board, Kevin Sayer, is taking a medical leave of absence.
- In a regulatory filing, the glucose monitoring equipment maker said that its board appointed Leach as interim principal executive officer effective Sept. 14 when Sayer’s medical leave also takes effect. Leach will continue to function as DXCM’s Chief Operating Officer in addition to his new role.
- Additionally, DexCom (NASDAQ:DXCM) has named Mark Foletta, lead independent director of its board, as its interim chairman of the board. Both Leach and Foletta will serve in their interim positions without receiving any extra compensation, the company added.
More on DexCom
- DexCom, Inc. (DXCM) Presents At Baird Global Healthcare Conference 2025 Transcript
- DexCom, Inc. (DXCM) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
- DexCom, Inc. 2025 Q2 - Results - Earnings Call Presentation
- DexCom down 6% as post Q2 earnings release slump continues
- DexCom raises 2025 revenue guidance to $4.625B as type 2 non-insulin access expands
推荐文章
美股机会日报 | 凌晨00:35！鲍威尔将发表重要讲话；阿里Qwen团队今晚将发布6个“新东西”
华盛早报 | 美联储理事米兰“首秀”，呼吁激进降息；英伟达涨近4%市值突破4.5万亿美元
美股机会日报 | 华尔街乐观押注：利率降幅将远超美联储预测！以太坊跳水重挫超5%，加密货币概念股BitMine盘前一度跌近10%
一图看懂 | 两只易方达ETF开启认购！入场门槛为1500港元
新股申购 | 博泰车联今起招股！一手入场费2065.23港元
美股“新宠”骤变：“昔日冷门”硬盘与内存站上AI风口 老牌存储厂商业绩股价齐飞
美联储政策路径不确定性仍存 中期美债备受交易员青睐
特朗普的H-1B签证10万美元新规引发科技公司混乱
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
